Michelson Diagnostics

Michelson Diagnostics Limited, founded in March 2006, develops and markets point-of-care, real-time tissue imaging devices. The company was established by five physicists and engineers: Jon Holmes, Bill Gilkes, Simon Hattersley, Martin Johns, and Gordon McKenzie. Jon Holmes, the CEO, holds an MA in Physics from the University of Cambridge and has over 30 years of experience in engineering.

The company's flagship product is the VivoSight Dx, a second-generation Optical Coherence Tomography (OCT) system. This non-invasive device uses eye-safe infrared laser light, an optical analogue to ultrasound, to produce high-resolution, cross-sectional images of the skin's subsurface layers up to a depth of 1mm. It is designed for dermatologists and researchers to visualize and measure skin structures and vascular networks, aiding in the diagnosis and monitoring of conditions like non-melanoma skin cancer. The system captures a 6mm x 6mm scan in as little as 15 seconds. The business model centers on the sale of these VivoSight OCT devices to clinical and research facilities.

Headquartered in Kent, England, the company also has subsidiaries in Germany and the US. In a 2021 collaboration, Michelson Diagnostics partnered with Manchester Imaging to develop artificial intelligence algorithms to automate the analysis of images from the VivoSight scanner, aiming to improve diagnostic accuracy and speed. The technology is supported by over 700 peer-reviewed publications.

Keywords: Optical Coherence Tomography, dermatology imaging, non-invasive diagnostics, skin cancer assessment, VivoSight, medical imaging technology, tissue imaging, subsurface imaging, dermatology research, point-of-care device, non-melanoma skin cancer, lesion analysis, clinical dermatology, medical device, transdermal applications, vascular imaging, multi-beam OCT, skin pathology, real-time imaging, diagnostic imaging